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In January 2013, the Swiss Medical Board, an inde-pendent health technology assessment initiative 
under the auspices of the Conference of Health  
Ministers of the Swiss Cantons, the Swiss Medical 
Association, and the Swiss Acad-
emy of Medical Sciences, was 
mandated to prepare a review of 
mammography screening. The 
two of us, a medical ethicist and 
a clinical epidemiologist, were 
members of the expert panel that 
appraised the evidence and its 
implications. The other members 
were a clinical pharmacologist, 
an oncologic surgeon, a nurse 
scientist, a lawyer, and a health 
economist. As we embarked on 
the project, we were aware of the 
controversies that have surround-
ed mammography screening for 
the past 10 to 15 years. When we 
reviewed the available evidence 
and contemplated its implica-
tions in detail, however, we be-
came increasingly concerned.
First, we noticed that the ongo-
ing debate was based on a series of 
reanalyses of the same, predomi-
nantly outdated trials. The first 
trial started more than 50 years 
ago in New York City and the last 
trial in 1991 in the United King-
dom.1 None of these trials were 
initiated in the era of modern 
breast-cancer treatment, which has 
dramatically improved the progno-
sis of women with breast cancer. 
Could the modest benefit of mam-
mography screening in terms of 
breast-cancer mortality that was 
shown in trials initiated between 
1963 and 1991 still be detected in 
a trial conducted today?
Second, we were struck by how 
nonobvious it was that the bene-
fits of mammography screening 
outweighed the harms. The rela-
tive risk reduction of approxi-
mately 20% in breast-cancer 
mortality associated with mam-
mography that is currently de-
scribed by most expert panels2 
came at the price of a consider-
able diagnostic cascade, with re-
peat mammography, subsequent 
biopsies, and overdiagnosis of 
breast cancers — cancers that 
would never have become clinical-
ly apparent. The recently pub-
lished extended follow-up of the 
Canadian National Breast Screen-
ing Study is likely to provide re-
liable estimates of the extent 
of overdiagnosis. After 25 years of 
follow-up, it found that 106 of 484 
screen-detected cancers (21.9%) 
were overdiagnosed.3 This means 
that 106 of the 44,925 healthy 
women in the screening group 
were diagnosed with and treated 
for breast cancer unnecessarily, 
which resulted in needless sur-
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gical interventions, radiotherapy, 
chemotherapy, or some combina-
tion of these therapies. In addi-
tion, a Cochrane review of 10 trials 
involving more than 600,000 
women showed there was no evi-
dence suggesting an effect of 
mammography screening on over-
all mortality.1 In the best case, the 
small reduction in breast-cancer 
deaths was attenuated by deaths 
from other causes. In the worst 
case, the reduction was canceled 
out by deaths caused by coexist-
ing conditions or by the harms 
of screening and associated over-
treatment. Did the available evi-
dence, taken together, indicate 
that mammography screening 
indeed benefits women?
Third, we were disconcerted 
by the pronounced discrepancy 
between women’s perceptions of 
the benefits of mammography 
screening and the benefits to be 
expected in reality. The figure 
shows the numbers of 50-year-
old women in the United States 
expected to be alive, to die from 
breast cancer, or to die from other 
causes if they are invited to under-
go regular mammography every 
2 years over a 10-year period, as 
compared with women who do 
not undergo mammography. The 
numbers in Panel A are derived 
from a survey about U.S. wom-
en’s perceptions,4 in which 717 
of 1003 women (71.5%) said they 
believed that mammography re-
duced the risk of breast-cancer 
deaths by at least half, and 723 
women (72.1%) thought that at 
least 80 deaths would be prevent-
ed per 1000 women who were in-
vited for screening. The numbers 
in Panel B reflect the most likely 
scenarios according to available 
trials1-3: a relative risk reduction 
of 20% and prevention of 1 breast-
cancer death. The data for Swit-
zerland, reported in the same 
study, show similarly overly op-
timistic expectations. How can 
women make an informed deci-
sion if they overestimate the ben-
efit of mammography so grossly?
The Swiss Medical Board’s re-
port was made public on February 
2, 2014 (www.medical-board.ch). 
It acknowledged that systematic 
mammography screening might 
prevent about one death attri-
buted to breast cancer for every 
1000 women screened, even 
though there was no evidence to 
suggest that overall mortality 
was affected. At the same time, 
it emphasized the harm — in 
particular, false positive test re-
sults and the risk of overdiagno-
sis. For every breast-cancer death 
prevented in U.S. women over a 
10-year course of annual screen-
ing beginning at 50 years of age, 
490 to 670 women are likely to 
have a false positive mammogram 
with repeat examination; 70 to 
100, an unnecessary biopsy; and 
3 to 14, an overdiagnosed breast 
cancer that would never have be-
come clinically apparent.5 The 
board therefore recommended 
that no new systematic mam-
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U.S. Women’s Perceptions of the Effects of Mammography Screening on Breast-Cancer Mortality 
as Compared with the Actual Effects.
Panel A shows the views of 50-year-old women in the United States regarding the effect of mammog-
raphy every 2 years on the 10-year risk of death from breast cancer (at left), as compared with no 
screening (at right). The areas of the squares are proportional to the numbers of women per 1000 
who would be alive (blue), die from breast cancer (orange), or die from other causes (yellow). 
The numbers were calculated from women’s perceived relative and absolute risk reductions for 
breast-cancer deaths (Domenighetti et al.4) and U.S. mortality statistics for 2008 from the Centers 
for Disease Control and Prevention. Panel B shows the actual effect of mammography screening 
on breast-cancer deaths, with numbers calculated from breast-cancer mortality data for 2008 from 
the National Cancer Institute and U.S. mortality statistics for 2008, assuming a relative risk reduction 
of 20% for breast-cancer mortality in women invited to undergo screening (Independent U.K. Panel2).
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mography screening programs 
be introduced and that a time 
limit be placed on existing pro-
grams. In addition, it stipulated 
that the quality of all forms of 
mammography screening should 
be evaluated and that clear and 
balanced information should be 
provided to women regarding the 
benefits and harms of screening.
The report caused an uproar 
and was emphatically rejected by 
a number of Swiss cancer experts 
and organizations, some of which 
called the conclusions “unethi-
cal.” One of the main arguments 
used against it was that it contra-
dicted the global consensus of 
leading experts in the field — a 
criticism that made us appreciate 
our unprejudiced perspective re-
sulting from our lack of expo-
sure to past consensus-building 
efforts by specialists in breast-
cancer screening. Another argu-
ment was that the report unset-
tled women, but we wonder how 
to avoid unsettling women, given 
the available evidence.
The Swiss Medical Board is 
nongovernmental, and its recom-
mendations are not legally bind-
ing. Therefore, it is unclear 
whether the report will have any 
effect on the policies in our 
country. Although Switzerland is 
a small country, there are nota-
ble differences among regions, 
with the French- and Italian-
speaking cantons being much 
more in favor of screening pro-
grams than the German-speaking 
cantons — a finding suggesting 
that cultural factors need to be 
taken into account. Eleven of the 
26 Swiss cantons have systematic 
mammography screening pro-
grams for women 50 years of age 
or older; two of these programs 
were introduced only last year. 
One German-speaking canton, 
Uri, is reconsidering its decision 
to start a mammography screen-
ing program in light of the 
board’s recommendations. Partic-
ipation in existing programs 
ranges from 30 to 60% — varia-
tion that can be partially ex-
plained by the coexistence of op-
portunistic screening offered by 
physicians in private practice. At 
least three quarters of all Swiss 
women 50 years of age or older 
have had a mammogram at least 
once in their life. Health insurers 
are required to cover mammog-
raphy as part of systematic screen-
ing programs or within the 
framework of diagnostic work-
ups of potential breast disease.
It is easy to promote mam-
mography screening if the major-
ity of women believe that it pre-
vents or reduces the risk of 
getting breast cancer and saves 
many lives through early detec-
tion of aggressive tumors.4 We 
would be in favor of mammogra-
phy screening if these beliefs 
were valid. Unfortunately, they are 
not, and we believe that women 
need to be told so. From an ethi-
cal perspective, a public health 
program that does not clearly 
produce more benefits than harms 
is hard to justify. Providing clear, 
unbiased information, promoting 
appropriate care, and preventing 
overdiagnosis and overtreatment 
would be a better choice.
The views expressed in this article are 
those of the authors and do not necessarily 
ref lect those of all members of the expert 
panel of the Swiss Medical Board.
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